echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Hepatol Int: The relationship between immune checkpoint inhibitor-mediated hepatitis and liver metastasis and clinical prognosis in patients with advanced melanoma

    Hepatol Int: The relationship between immune checkpoint inhibitor-mediated hepatitis and liver metastasis and clinical prognosis in patients with advanced melanoma

    • Last Update: 2021-07-31
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Immune checkpoint inhibitor-mediated hepatitis is a common immune-related adverse event in the treatment of programmed cell death protein 1 (PD-1) inhibitors, cytotoxic T lymphocyte-related 4 (CTLA-4) inhibitors, or a combination of the two
    .


    The purpose of this real-world study is to evaluate whether immune checkpoint inhibitor-mediated hepatitis is associated with liver metastasis and clinical prognosis in patients with advanced melanoma


    Immune checkpoint inhibitor-mediated hepatitis is a common immune-related adverse event in the treatment of programmed cell death protein 1 (PD-1) inhibitors, cytotoxic T lymphocyte-related 4 (CTLA-4) inhibitors, or a combination of the two


    Between May 2012 and January 2019, 2561 patients with advanced cutaneous melanoma received 3111 immune checkpoint inhibitor treatments
    .


    Among them, 1620 cases received PD1 inhibitor treatment, 1105 cases received ipilimumab treatment, and 386 cases received combined treatment


    Between May 2012 and January 2019, 2561 patients with advanced cutaneous melanoma received 3111 immune checkpoint inhibitor treatments


    Research Overview

    Research Overview

    Among 1620 patients treated with PD-1 inhibition, 1048 (65%) were first-line treatment
    .


    Of the remaining 572 patients, 239 (15%) received ipilimumab therapy, 24 (1%) received combination therapy, and 309 (19%) received BRAF or BRAF/MEK inhibitor therapy


    Among 1620 patients treated with PD-1 inhibition, 1048 (65%) were first-line treatment


    Compared with non-hepatitis patients, the incidence of liver metastases in hepatitis patients was similar (32% vs.


    There was no difference between median progression-free survival (PFS) and overall survival (OS) in patients with and without hepatitis (PFS: 6.


    Prognostic factors of PFS and OS

     Prognostic factors of PFS and OS

    3 patients (10%) of PD-1 inhibitor-mediated hepatitis had additional immunotherapy-related adverse events (IRAEs), and 10 patients (34%) of ipilimumab-mediated hepatitis, and combined There were 29 cases (36%) in treatment
    .


    The additional IRAEs mainly included 17 cases of endocrine toxicity, 13 cases of gastrointestinal toxicity, and 10 cases of skin toxicity


    3 patients (10%) of PD-1 inhibitor-mediated hepatitis had additional immunotherapy-related adverse events (IRAEs), and 10 patients (34%) of ipilimumab-mediated hepatitis, and combined There were 29 cases (36%) in treatment


    Other immunotherapy-related adverse events

    Other immunotherapy-related adverse events

    In summary, in the real cohort of advanced melanoma treatment, the incidence of PD-1 inhibitor hepatitis was 1.
    8%, ipilimumab was 2.
    6%, and the combined treatment was 20.
    7%
    .


    Immune checkpoint inhibitor-mediated hepatitis is not significantly related to liver metastasis, and has no negative impact on clinical prognosis


    In summary, in the real cohort of advanced melanoma treatment, the incidence of PD-1 inhibitor hepatitis was 1.
    8%, ipilimumab was 2.
    6%, and the combined treatment was 20.
    7%
    .
    Immune checkpoint inhibitor-mediated hepatitis is not significantly related to liver metastasis, and has no negative impact on clinical prognosis
    .
    In the real cohort of advanced melanoma treatment, the incidence of PD-1 inhibitor hepatitis was 1.
    8%, ipilimumab was 2.
    6%, and the combined treatment was 20.
    7%
    .
    Immune checkpoint inhibitor-mediated hepatitis is not significantly related to liver metastasis, and has no negative impact on clinical prognosis
    .
    In the real cohort of advanced melanoma treatment, the incidence of PD-1 inhibitor hepatitis was 1.
    8%, ipilimumab was 2.
    6%, and the combined treatment was 20.
    7%
    .
    Immune checkpoint inhibitor-mediated hepatitis is not significantly related to liver metastasis, and has no negative impact on clinical prognosis
    .

    Original source:

    Original source:

    Biewenga M, van der Kooij MK, Wouters MWJM, et al.
    Checkpoint inhibitor induced hepatitis and the relation with liver metastasis and outcome in advanced melanoma patients.
    Hepatol Int.
    2021 Apr;15(2):510-519.
    doi: 10.
    1007/ s12072-021-10151-4.

    Biewenga M, van der Kooij MK, Wouters MWJM, et al.
    Checkpoint inhibitor induced hepatitis and the relation with liver metastasis and outcome in advanced melanoma patients.
    Hepatol Int.
    2021 Apr;15(2):510-519.
    doi: 10.
    1007/ s12072-021-10151-4.
    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.